Zoladex LA 10.8mg depot subkutan implant iceren kullanima hazir enjektor goserelin

Generic Name: Goserelin Acetate Sustained-Release Implant

Brand Name: Zoladex

English Name: Goserelin Acetate Sustained-Release Implant

Manufacturer: AstraZeneca

Composition

Active Ingredient: Goserelin Acetate

Specification: 10.8 mg/implant

Description

This product is a white or off-white, cylindrical, sustained-release implant, pre-loaded in a disposable syringe.

[Indications]

Prostate Cancer: Used for the palliative treatment of advanced prostate cancer.

Breast Cancer: Used for the treatment of hormone receptor-positive breast cancer in premenopausal and perimenopausal women.

Endometriosis: Used to alleviate symptoms and reduce endometriotic lesions.

Uterine Fibroids: Used preoperatively to reduce fibroid volume or alleviate associated symptoms.

Precocious Puberty: Sometimes also used for the treatment of central precocious puberty in children.

[Dosage and Administration]

Recommended Dosage: Administer one subcutaneous injection of 10.8 mg every 12 weeks.

Injection Site: Subcutaneous injection into the anterior abdominal wall; alternate between the left and right sides.

Method of Administration: To be administered by a trained healthcare professional to ensure proper implantation of the syringe.

[Adverse Reactions]

Common adverse reactions include:

Male Patients: Hot flashes, decreased libido, erectile dysfunction, injection site reactions.

Female Patients: Hot flashes, hyperhidrosis (excessive sweating), decreased libido, vaginal dryness, mood swings.

Others: Headache, decreased bone density (with long-term use), abnormal liver function.

[Contraindications]

Contraindicated in patients with known hypersensitivity to goserelin or to any of the excipients in this product.

Contraindicated in pregnant women.

Use with caution in breastfeeding women.

[Precautions]

Effect on Bone Density: Long-term use may lead to a decrease in bone density; periodic monitoring is recommended.

Diabetes Risk: May affect blood glucose control; diabetic patients require close monitoring of blood glucose levels.

Cardiovascular Risk: May increase the risk of cardiovascular events; use with caution in high-risk patients.

Injection Site Reactions: Local pain, redness, or swelling may occur after injection; these symptoms typically resolve spontaneously. [Drug Interactions]

Hormonal Medications: Avoid concurrent use with other hormonal medications.

Anticoagulants: May increase the risk of bleeding; close monitoring is required.

[Pharmacological Action]

Goserelin is a gonadotropin-releasing hormone (GnRH) analog that exerts its therapeutic effect by continuously suppressing the secretion of pituitary gonadotropins, thereby lowering sex hormone levels.

[Storage]

Store below 25°C. Do not freeze.

Keep out of the reach of children.

[Packaging]

One syringe per box, pre-filled in a disposable syringe.

[Shelf Life]

36 months.

[Important Notice]

This product is a prescription medication and must be used under the guidance of a physician.

Please read the package insert carefully before use; if you have any questions, please consult a physician or pharmacist.

Do not use this product for indications not listed in the package insert.

[Product Specifications]

Product Name: Zoladex LA 10.8mg (Goserelin Acetate Sustained-Release Implant)

Common Name: Zoladex

Composition: Goserelin Acetate

Dosage Form: A white or off-white cylindrical sustained-release implant, pre-filled in a disposable syringe.

Specification: 10.8 mg/syringe

Manufacturer: AstraZeneca

Indications: Prostate Cancer: Used for the palliative treatment of advanced prostate cancer.

Breast Cancer: Used for the treatment of hormone receptor-positive breast cancer in premenopausal and perimenopausal women.

Endometriosis: Used to alleviate symptoms and reduce endometriotic lesions.

Uterine Fibroids: Used preoperatively to reduce fibroid volume or alleviate associated symptoms.

Precocious Puberty: Sometimes used to treat central precocious puberty in children.

Dosage and Administration: Recommended Dose: Administer via subcutaneous injection once every 12 weeks, at a dose of 10.8 mg per injection.

Injection Site: Subcutaneous injection into the anterior abdominal wall; alternate between the left and right sides.

Method of Administration: To be administered by a trained healthcare professional to ensure proper implantation of the syringe.